Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Masonic Cancer Center, University of Minnesota
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06411795CT.gov Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Tumor Of Duodenum
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Hydromorphon (this asset) | Masonic Cancer Center, University of Minnesota | P2 | CCC · 53 |
| Ursodeoxycholic Acid | Radboud University Medical Center | P2/3 | B |
| Celecoxib | Radboud University Medical Center | P2/3 | B |
| Marcaine | Masonic Cancer Center, University of Minnesota | P2 | CCC |
| Iopamidol | Masonic Cancer Center, University of Minnesota | P2 | CCC |
| L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))- | St. James's Hospital, Ireland | N/A | D |
Other indications for Hydromorphon
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Substance-Related Disorder | — | P4 | BBB · 74 |
| Cancer | — | P4 | BB · 68 |
| Post-Operative Pain, Non-Human Animal | — | P4 | BB · 67 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Ursodeoxycholic AcidRadboud University Medical CenterB
- CelecoxibRadboud University Medical CenterB
- MarcaineMasonic Cancer Center, University of MinnesotaCCC
- IopamidolMasonic Cancer Center, University of MinnesotaCCC
- L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))-St. James's Hospital, IrelandD
Citation
Floatz Terminal. Hydromorphon in Tumor Of Duodenum. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/hydromorphon-tumor-of-duodenum
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →